TP53 缺失通过上调 NF-κB-IFN-β-MHC-Ia 信号促进骨肉瘤对 NK 细胞的抵抗
TP53 Loss Elevates NF-κB-IFN-β-MHC-Ia Signaling to Promote NK Cell Resistance in Osteosarcoma.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
改善间充质干细胞治疗炎症性肠病效果的策略
英文原题：Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease.
查看英文原题
Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
炎症性肠病（IBD）包括克罗恩病和溃疡性结肠炎，是一种特发性的结肠黏膜慢性炎症性疾病。IBD的发生会对结肠造成不可逆的损伤，并增加癌变风险。IBD的常规临床治疗包括药物治疗、内镜治疗和手术治疗。绝大多数患者接受药物和生物制剂治疗，但IBD难以完全治愈。间充质干细胞（MSCs）因其免疫调节和营养功能已成为治疗IBD的新型细胞疗法，并已在多项临床试验中得到证实。本综述讨论了MSCs治疗IBD的一些潜在机制，总结了实验结果，并为未来应用中增强MSCs的治疗效果提供了新的见解。
展开英文摘要原文
Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis and is an idiopathic, chronic inflammatory disease of the colonic mucosa. The occurrence of IBD, causes irreversible damage to the colon and increases the risk of carcinoma. The routine clinical treatment of IBD includes drug treatment, endoscopic treatment and surgery. The vast majority of patients are treated with drugs and biological agents, but the complete cure of IBD is difficult.
Mesenchymal stem cells (MSCs) have become a new type of cell therapy for the treatment of IBD due to their immunomodulatory and nutritional functions, which have been confirmed in many clinical trials. This review discusses some potential mechanisms of MSCs in the treatment of IBD, summarizes the experimental results, and provides new insights to enhance the therapeutic effects of MSCs in future applications.
论文信息
- 作者
- Shi MY、Liu L、Yang FY
- 第一作者单位
- School of Medicine, Yangtze University, Jingzhou 434023, Hubei Province, China.China
- 通讯作者单位
- Health Science Center, Yangtze University, Jingzhou 434020, Hubei Province, China. ivansblue@sina.com.China
- 文献类型
- 综述
- 期刊
- World journal of stem cells2022 Sep 26
- 原文标识
- PubMed 36188115 · DOI 10.4252/wjsc.v14.i9.684
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →